Weekly bladder radiation shows promise for patients unable to have standard treatment

NCT ID NCT01810757

Completed Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a weekly, higher-dose radiation schedule (hypofractionated radiotherapy) for people with muscle-invasive bladder cancer who cannot have standard daily radiation or surgery. It included 65 participants and compared standard radiation planning with a newer 'adaptive' technique that adjusts the radiation field each session based on the bladder's changing shape. The goal was to see if this approach is safe and effective at controlling the tumor while reducing side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, United Kingdom
Clatterbridge Cancer Centre

Metropolitan Borough of Wirral, United Kingdom
Guy's & St Thomas's Hospital

London, United Kingdom
Ipswich Hospital

Ipswich, United Kingdom
Norfolk & Norwich University Hospitals NHS Foundation Trust

Norwich, United Kingdom
Queens Hospital

Romford, United Kingdom
Royal Marsden NHSFT

London, United Kingdom
Royal Preston Hospital

Preston, United Kingdom
St James's University Hospital

Leeds, United Kingdom
University College London

London, United Kingdom
Velindre Cancer Centre

Cardiff, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.